Chris Schott
Stock Analyst at JP Morgan
(3.60)
# 785
Out of 4,784 analysts
125
Total ratings
57.32%
Success rate
3%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $110.82 | +17.31% | 5 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $8.27 | +45.19% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $202.86 | -1.41% | 2 | Nov 13, 2024 | |
| BIIB Biogen | Maintains: Neutral | $220 → $210 | $139.08 | +50.99% | 3 | Nov 4, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,150 | $632.31 | +81.87% | 5 | Oct 24, 2024 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Neutral | $16 → $18 | $15.26 | +17.99% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $420.11 | +36.87% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $164.76 | +39.60% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $822.46 | +33.75% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $14.46 | +38.36% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $27.56 | +48.79% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $31.15 | +34.83% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $305.82 | -11.71% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.87 | +36.71% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $88.74 | +40.86% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $8.79 | +59.36% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.85 | +1,191.08% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $10.65 | +87.88% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.57 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $58.97 | +32.28% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $5.91 | +15,974.45% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.07 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.43 | +96.66% | 3 | Nov 2, 2018 |
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $110.82
Upside: +17.31%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.27
Upside: +45.19%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $202.86
Upside: -1.41%
Biogen
Nov 4, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $139.08
Upside: +50.99%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Overweight
Price Target: $1,200 → $1,150
Current: $632.31
Upside: +81.87%
Teva Pharmaceutical Industries
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $15.26
Upside: +17.99%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $420.11
Upside: +36.87%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $164.76
Upside: +39.60%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $822.46
Upside: +33.75%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $14.46
Upside: +38.36%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $27.56
Upside: +48.79%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $31.15
Upside: +34.83%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $305.82
Upside: -11.71%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.87
Upside: +36.71%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $88.74
Upside: +40.86%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $8.79
Upside: +59.36%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.85
Upside: +1,191.08%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $10.65
Upside: +87.88%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.57
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $58.97
Upside: +32.28%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $5.91
Upside: +15,974.45%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.43
Upside: +96.66%